Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech

On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicine ‘Human IgG1 monoclonal antibody specific for human interleukin\-1 alpha XBiotech’, intended for intended for treating debilitating symptoms of advanced colorectal cancer. The company that applied for authorisation is XBiotech Germany GmbH. The company requested a re\-examination of the opinion. After considering the grounds for this request, the CHMP re\-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 14 September 2017\.